Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

Kronenberg, 1994, Hot flashes, 97 Schiff, 1979, Effects of estrogens on sleep and psychological state of hypogonadal women, J. Am. Med. Assoc., 242, 2404, 10.1001/jama.242.22.2405 Yen, 1972, Gonadotropin dynamics in patients with gonadal dysgenesis: a model for the study of gonadotropin regulation, J. Clin. Endocrinol. Metab., 35, 897, 10.1210/jcem-35-6-897 Aksel, 1976, Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause, Am. J. Obstet. Gynecol., 126, 165, 10.1016/0002-9378(76)90270-2 Tataryn, 1980, Postmenopausal hot flushes: a disorder of thermoregulation, Maturitas, 2, 101, 10.1016/0378-5122(80)90043-2 Hemminki, 1991, Use of estrogens among middle-aged Massachusetts women, Ann. Pharmacother., 25, 418 Kronenberg, 1990, Hot flashes: epidemiology and physiology, Ann. N. Y. Acad. Sci., 594, 52, 10.1111/j.1749-6632.1990.tb30316.x Rozenberg, 1996, Decision factors influencing hormone replacement therapy, Br. J. Obstet. Gynaecol., 103, 92 Porter, 1996, A population based survey of women’s experience of the menopause, Br. J. Obstet. Gynaecol., 103, 1025, 10.1111/j.1471-0528.1996.tb09555.x Stadberg, 1997, The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population, Acta Obstet. Gynecol. Scand., 76, 442, 10.3109/00016349709047826 Feldman, 1985, The prevalence of hot flash and associated variables among perimenopausal women, Res. Nurs. Health, 8, 261, 10.1002/nur.4770080308 McKinlay, 1996, The normal menopause transition: an overview, Maturitas, 23, 137, 10.1016/0378-5122(95)00985-X Thompson, 1973, Menopausal age and symptomatology in a general practice, J. Biosoc. Sci., 5, 71, 10.1017/S0021932000008956 Berg, 1988, Climacteric symptoms among women aged 60–62 in Linkoping, Sweden, in 1986, Maturitas, 10, 193, 10.1016/0378-5122(88)90022-9 Mitlak, 1999, Selective estrogen receptor modulators: a look ahead, Drugs, 57, 653, 10.2165/00003495-199957050-00001 Barrett-Connor, 1999, Effects of selective estrogen receptor modulators on lipids and the vasculature. The potential for protection against cardiovascular disease, Trends Endocrinol. Metab., 10, 320, 10.1016/S1043-2760(99)00182-4 Wu, 1999, Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase in ovariectomized rats, Brain Res., 847, 98, 10.1016/S0006-8993(99)02062-4 Bryant, 1997, Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain, Soc. Neurosci., 23, 2377 Cohen, 1998, Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women, Calcif. Tissue Int., 63, 277, 10.1007/s002239900526 Delmas, 1997, Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, N. Eng. J. Med., 337, 1641, 10.1056/NEJM199712043372301 Cox, 1972, Regression models and life-tables (with discussion), J. R. Statist. Soc., B34, 187 Cox, 1984, 37 McCullough, 1989, 193 Draper, 1996, J. Bone Miner. Res., 11, 835, 10.1002/jbmr.5650110615 United States Package Insert for Fareston (toremifene), December 1997. United States Package Insert for Nolvadex (tamoxifen citrate), March 1996. United States Package Insert for Clomid (clomiphene citrate), February 1996. Ettinger, 1996, Continuation of postmenopausal hormone replacement therapy: comparison of cyclic compared with continuous combined schedules, Menopause, 5, 185, 10.1097/00042192-199603040-00003 Salamone, 1996, Estrogen replacement therapy. A survey of older women’s attitudes, Arch. Intern. Med., 156, 1293, 10.1001/archinte.156.12.1293 Gass, 1997, Characteristics of women who continue using hormone replacement therapy, N. Am. Menopause Soc., 4, 19 United States Package Insert for Prempro (conjugated estrogens/medroxyprogestserone acetate USP). United States Package Insert for Evista (raloxifene hydrochloride), September 30, 1999. Castellsague, 1998, Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review, Drug Saf., 18, 117, 10.2165/00002018-199818020-00003 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial, J. Am. Med. Assoc., 282, 637, 10.1001/jama.282.7.637 Davies, 1999, The endometrial response to raloxifene compared with placebo, hormone replacement therapy, and unopposed estrogen in postmenopausal women, Obstet. Gynecol., 93, 558, 10.1016/S0029-7844(98)00476-1 Goldstein SR, Scheele WH, Rajagopalan SR, et al. A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium, Obstet Gynecol, in press. Lufkin, 1998, Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial, J. Bone Miner. Res., 13, 1747, 10.1359/jbmr.1998.13.11.1747 Meunier PJ, Vignot E, Garnero P, et al. for the Raloxifene Study Group. Treatment of postmenopausal osteoporosis with raloxifene, Osteoporosis Int, in press. Haas, 1988, The effect of transdermal estradiol on hormone and metabolic dynamics over a 6-week period, Obstet. Gynecol., 71, 671 Steingold, 1985, Treatment of hot flashes with transdermal estradiol administration, J. Clin. Endocrinol. Metab., 61, 627, 10.1210/jcem-61-4-627